Oslo, Norway - May 6, 2008: NorDiag ASA (OSE:NORD) announced today a new collaboration agreement with EXACT Sciences for the joint, scientific development of an automated nucleic acid sample purification system from stool samples for the screening and early diagnosis of colorectal cancer. Advanced automation of nucleic acid sample purification from stool can provide significant cost savings and streamline the processing of the colorectal cancer assays using EXACT Sciences` stool DNA (sDNA) technologies. By collaborating on sample preparation techniques, there is greater opportunity to accelerate and optimize the development of non-invasive, low-cost molecular techniques and tools for the early detection of colorectal cancer. Innovations derived from this collaboration may benefit the tens of millions of people worldwide who should have regular screening for colorectal cancer.

With the recent guidelines endorsement of EXACT Sciences` DNA technologies by the American Cancer Society and the U.S. Multi-Society Task Force for Colorectal Cancer Screening, as well as the recommendation last year by The World Gastroenterology Organisation to include sDNA screening in the international screening guidelines, NorDiag`s automation solutions can potentially support the processing of increased test volumes over time. NorDiag`s extensive expertise in nucleic acid purification from difficult samples can provide substantial benefit in standardizing the purification of DNA from stool samples, which is a major cost driver of stool DNA testing.

This collaboration is different from, and in addition to, the collaboration and license agreement entered into between NorDiag and EXACT Sciences in June 2007. The new agreement expands the technology covered and the joint efforts of both companies. It also gives EXACT Sciences exclusive marketing rights of the technology in the United States and Canada, and exclusive marketing rights to NorDiag outside of such territory. In connection with this collaboration agreement, EXACT Sciences also received an exclusive right of first refusal in the U.S. and Canada to any NorDiag sample preparation advancements in the field of screening and early diagnosis of colorectal cancer where stool is the sample type.

`We are very pleased to work closely with the leading U.S. company in molecular technologies for colorectal cancer screening,` said Mårten Wigstøl, CEO of NorDiag. `We believe scientific collaborations by leading companies in the field are the best way to win the race of making the best tools for early detection of colorectal cancer.`

`NorDiag offers significant skills and expertise in the area of sample preparation and automation solutions,` said Jeff Luber, President and CEO of EXACT Sciences. `Their relationship with Roche Diagnostics AB that was announced last year is a testament to their unique offering. We are very pleased to have entered into this scientific collaboration and license arrangement with NorDiag, as we consider avenues for further optimization and scalability of sDNA testing.`

Colorectal cancer mortality is a global problem. Worldwide there are more than 900,000 new cases diagnosed annually and with 500,000 deaths it is the second most deadly cancer. In Europe alone there are 100 million people over the age of 50 that should be screened for colorectal cancer and it is estimated that a third of CRC-related deaths could be prevented if more people underwent regular screening. New screening options such as those based on EXACT`s and NorDiag`s technologies can help address this problem and have the potential to increase screening rates for this deadly, but curable disease if caught early.

Contact:
CEO Mårten Wigstøl, phone + 47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 34 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Go to the Stock Exchange Notice here

Read the Stock Exchange Notice in Norwegian here